Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-02-01
1996-03-12
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142265, 5142305, 514299, 514311, 514312, 514314, 514360, 514373, 514375, 514414, C07D21516
Patent
active
054986109
ABSTRACT:
The present invention is directed to a method of blocking N-methyl-D-aspartic (NMDA) acid receptor sites in a mammal in need thereof with an effective NMDA blocking (neuroprotective and antiischemic) amount of 5-(1-hydroxy-2-piperidino)-propyl-2(1H,3H)-indolone analogs and the pharmaceutically acceptable salts thereof; methods of using these compounds in the treatment of stroke, head trauma, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised.
REFERENCES:
patent: 3294804 (1966-12-01), Carabateas
patent: 3509164 (1970-04-01), Carron et al.
patent: 4082755 (1978-04-01), van Wijngaarden
patent: 4304915 (1981-12-01), Berthold
patent: 4358456 (1982-11-01), Ward
patent: 4393069 (1983-07-01), Langbein et al.
patent: 4902695 (1990-02-01), Ornstein
patent: 5034401 (1991-07-01), Frost et al.
patent: 5185343 (1993-02-01), Chenard
patent: 5192751 (1993-03-01), Thor
patent: 5272160 (1993-12-01), Chenard
patent: 5352683 (1994-10-01), Mayer et al.
CA115:8584g Preparation . . . agents. Chenard, p. 838, 1991.
CA116:83552u Preparation . . . neuroprotectants. Chenard, p. 807, 1992.
Greenamyre & Young, Neurobiology of Aging, 10, 1989, pp. 593-602.
Meldrum & Garthwaite, Trends in Pharmacology Sci., 11, 1990, pp. 379-387.
Gotti et al., J. Pharmacol. Exp. Therap., vol. 247, pp. 1211-1222 (1988).
Hansen and Krogsgaard-Larsen, Med. Res. Rev., 10, pp. 55-94 (1990).
Carter et al., J. Pharmacol. Exp. Therap., vol. 247, pp. 1222-1232 (1988).
Murphy et al., British J. Pharmacol., 95, pp. 932-938 (1988).
CA86:189738m, Nakagawa et al., p. 592, 1977.
Harrison and Simmonds, British J. Pharmacol., 84, pp. 381-391 (1984).
CA89:43498y; Derwent 14858A, Tomio et al., p. 644, 1978.
Schoepp et al., J. Neur. Transm., 85, pp. 131-143 (1991).
CA89:146938w; Derwent 48671A, Tomio et al., p. 615, 1978.
Carron et al., Arneim-Forsch, vol. 21, pp. 1992-1998 (1971).
Trujillo and Akil, Science, 251, p. 85, (1991).
Bonte et al., Eur. J. Med. Chem. 25 (4), pp. 361-368 (1990).
J. Lehmann et al., PIPS, 11, p. 1, (1990).
J. Lehmann, The NMDA Receptor, Drugs of the Future, 14, No. 11, pp. 1059-1071, (1989).
Benson Gregg C.
Conway John D.
McKane Joseph K.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Neuroprotective indolone and related derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective indolone and related derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective indolone and related derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100096